BioMedNewsBreaks Archive - BioMedWire (BMW)

ThursdayJun 11, 2026 3:58 pm

BioMedNewsBreaks — OptimizeRx Corp. (NASDAQ: OPRX) Secures $35 Million Senior Credit Facility

OptimizeRx (NASDAQ: OPRX), a provider of healthcare technology solutions for life sciences companies, announced that it has entered into a $35 million senior secured credit facility with Fifth Third Bank. The facility consists of a $25 million term loan and a $10 million revolving credit facility that was undrawn at closing. Roth Capital Partners served as financial advisor on the transaction. To view the full announcement, visit https://ibn.fm/G0Fj3 About OptimizeRx OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant,…

ThursdayJun 11, 2026 2:32 pm

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Accelerates Development Strategy for Lead Candidate

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, was featured in a recent article that discussed the company’s efforts beginning a key phase of preclinical development for its lead drug candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes. The publication reads, “The company is initiating a Good Laboratory Practice (‘GLP’) toxicology and pharmacology program aligned with U.S. Food and Drug Administration (‘FDA’) requirements, intended to support an Investigational New Drug (‘IND’) application and represents a necessary step before first-in-human clinical trials.…

ThursdayJun 11, 2026 10:40 am

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Completes Business Combination and Begins Trading on Nasdaq

VERAXA Biotech (NASDAQ: VRXA) announced the successful closing of its previously announced business combination with Voyager Acquisition Corp. (NASDAQ: VACH), resulting in the formation of VERAXA Biotech AG, which will begin trading on the Nasdaq Capital Market under the ticker symbol VRXA, with warrants trading under VRXAW. The company is developing a pipeline of bispecific T-cell engagers and antibody-drug conjugates based on its proprietary BiTAC platform, which is designed to selectively target cancer cells while sparing healthy tissue. VERAXA said proceeds from recently completed financings, including a $27.5 million senior secured note and a securities purchase agreement of up to…

WednesdayJun 10, 2026 9:30 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Highlights Fiscal 2026 Growth and Cash Flow Progress in Shareholder Letter

Earth Science Tech (OTC: ETST) provided a business update in a letter to shareholders, highlighting what management described as a transformational fiscal year ended March 31, 2026. The company cited progress across multiple holdings, including the expansion of Mister Meds, turnarounds at DOConsultation and Villas Health, the relaunch of MyOnlineConsultation as a cash flow-positive prescriber network and revenue growth at Peaks that surpassed $2 million during the first week of the fourth quarter. Earth Science Tech said it completed these initiatives without adding debt to its balance sheet, while also repurchasing and retiring more than 3.7 million shares during the…

WednesdayJun 10, 2026 9:10 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) Advances ONC010 Manufacturing Process Development

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) announced the initiation of process development and intermediate scale-up activities for A83B4C63, the active pharmaceutical ingredient in its proprietary drug candidate ONC010. The work represents a key milestone in the company's chemistry, manufacturing and controls strategy as it advances toward IND-enabling studies and planning for first-in-human clinical evaluation. Onco said the program will focus on optimizing synthetic processes, improving yield and reproducibility and scaling production of key intermediates required for downstream manufacturing and formulation. The…

TuesdayJun 09, 2026 9:40 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Delivers First Edge AI Intoxication Detection Kiosk Prototypes

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio’s Edge AI Kiosks Use Voice and AI to detect intoxication and fatigue. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced the completion and delivery of its first prototype Edge AI Intoxication Detection Kiosks, a hardware and software platform designed to detect intoxication and fatigue through AI-powered voice analysis. The kiosks are intended for workplace environments and are being developed to help improve safety across industries where drug, alcohol and fatigue monitoring are critical. The company said the prototypes will now undergo testing,…

MondayJun 08, 2026 1:15 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Oversubscribed $22.5 Million Financing and Growth Strategy in Investor Presentation

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in a virtual investor segment featuring Chief Financial Officer Steve O'Loughlin, who discussed the company's recently completed oversubscribed $22.5 million financing. The presentation focused on the factors supporting the successful capital raise following CNS Pharmaceuticals' strategic reset and acquisition-focused transformation. Management also addressed investor reception to the company's evolving strategy, the participation of healthcare-focused institutional investors and how the strengthened balance sheet positions CNS Pharmaceuticals to pursue potential transformational opportunities. The discussion highlighted the company's long-term growth strategy and efforts to create shareholder value as it advances its next phase of development. To…

MondayJun 08, 2026 12:00 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances European Commercial Launch Plans for GelrinC

Regentis Biomaterials (NYSE American: RGNT) announced plans to begin European surgeon training activities in the third quarter of 2026 as part of preparations for the commercial rollout of GelrinC(R), its CE Mark-approved treatment for knee cartilage lesions. The hands-on program will provide orthopedic surgeons with practical experience using the company's cell-free implant and is expected to begin at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe. The company said the training initiative is a key step in its European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance and knowledge sharing. GelrinC is designed as…

MondayJun 08, 2026 11:45 am

BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Advances Ibogaine Drug Development Program

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising. Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced progress on its Ibogaine Initiative, securing naturally derived ibogaine from two sources in both hydrochloride and freebase forms. The company expects development of finished ibogaine drug products to begin this summer at its GMP-certified manufacturing facility in British Columbia, with plans to produce standardized 50 mg and 100 mg encapsulated dosage formats for research and regulated access programs. The update comes amid growing interest in ibogaine research and expanding public funding for psychedelic therapies, including a recently announced $50 million program in Texas. Optimi said its development program…

MondayJun 08, 2026 11:35 am

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF)(Frankfurt: W1H) (WKN: A3EKSZ) Signs LOI to Advance ONC010 Development, Appoints VP of Corporate Finance

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) announced it has entered into a non-binding letter of intent with Nanosoft Polymers as an initial step toward negotiating a services agreement supporting development of its exclusively licensed PNKP inhibitor technology, ONC010. The proposed collaboration would focus on polymer process development, analytical characterization, formulation optimization and manufacturing planning activities designed to support future clinical and regulatory development of the oncology candidate. The company also appointed Dave Antony as vice president of corporate finance. Antony brings more than 35 years of experience in financial planning, reporting, corporate governance and public company advisory services, including leadership roles…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — OptimizeRx Corp. (NASDAQ: OPRX) Secures $35 Million Senior Credit Facility

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Accelerates Development Strategy for Lead Candidate

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Completes Business Combination and Begins Trading on Nasdaq

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Highlights Fiscal 2026 Growth and Cash Flow Progress in Shareholder Letter

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) Advances ONC010 Manufacturing Process Development

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Delivers First Edge AI Intoxication Detection Kiosk Prototypes

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Oversubscribed $22.5 Million Financing and Growth Strategy in Investor Presentation

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances European Commercial Launch Plans for GelrinC

BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Advances Ibogaine Drug Development Program

BioMedNewsBreaks — Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF)(Frankfurt: W1H) (WKN: A3EKSZ) Signs LOI to Advance ONC010 Development, Appoints VP of Corporate Finance

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search